Trocoxil

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
05-05-2020

Ingredient activ:

mavacoxib

Disponibil de la:

Zoetis Belgium SA

Codul ATC:

QM01AH92

INN (nume internaţional):

mavacoxib

Grupul Terapeutică:

Dogs

Zonă Terapeutică:

Anti inflammatory and antirheumatic products

Indicații terapeutice:

For the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated.

Rezumat produs:

Revision: 10

Statutul autorizaţiei:

Authorised

Data de autorizare:

2008-09-09

Prospect

                                15
B. PACKAGE LEAFLET
16
PACKAGE LEAFLET:
TROCOXIL 6 MG CHEWABLE TABLETS FOR DOGS
TROCOXIL 20 MG CHEWABLE TABLETS FOR DOGS
TROCOXIL 30 MG CHEWABLE TABLETS FOR DOGS
TROCOXIL 75 MG CHEWABLE TABLETS FOR DOGS
TROCOXIL 95 MG CHEWABLE TABLETS FOR DOGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM
Manufacturer responsible for batch release:
Pfizer Italia s.r.l.
Località Marino del Tronto
63100 Ascoli Piceno (AP)
ITALY
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Trocoxil 6 mg chewable tablets for dogs
Trocoxil 20 mg chewable tablets for dogs
Trocoxil 30 mg chewable tablets for dogs
Trocoxil 75 mg chewable tablets for dogs
Trocoxil 95 mg chewable tablets for dogs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ACTIVE SUBSTANCE:
Mavacoxib
6 mg
Mavacoxib
20 mg
Mavacoxib
30 mg
Mavacoxib
75 mg
Mavacoxib
95 mg
Tablets also contain the following ingredients:
Sucrose
Silicified microcrystalline cellulose
Artificial powdered beef flavour
Croscarmellose sodium
Sodium laurylsulfate
Magnesium stearate
Triangular tablet with mottled brown appearance embossed with the
tablet strength on one side, the
reverse side is blank.
17
4.
INDICATION(S)
Trocoxil chewable tablets are indicated for the treatment of pain and
inflammation associated with
degenerative joint disease in dogs where treatment for more than one
month is needed.
Trocoxil belongs to a group of medicines called Non-steroidal
Anti-inflammatory drugs (NSAIDs)
which are used to treat pain and inflammation.
5.
CONTRAINDICATIONS
Do not use in dogs less than 12 months of age and/or less than 5 kg
body weight.
Do not use in dogs suffering from gastro-intestinal disorders
including ulceration and bleeding.
Do not use where there is evidence of a haemorrhagic disorder.
Do not use in cases of impaired kidney or liver function.
Do not use in cases of heart insufficiency.

                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Trocoxil 6 mg chewable tablets for dogs
Trocoxil 20 mg chewable tablets for dogs
Trocoxil 30 mg chewable tablets for dogs
Trocoxil 75 mg chewable tablets for dogs
Trocoxil 95 mg chewable tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCE:
Mavacoxib
6 mg
Mavacoxib
20 mg
Mavacoxib
30 mg
Mavacoxib
75 mg
Mavacoxib
95 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablets
Triangular tablet with mottled brown appearance embossed with the
tablet strength on one side, the
reverse side is blank.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs aged 12 months or more.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of pain and inflammation associated with
degenerative joint disease in dogs in cases
where continuous treatment exceeding one month is indicated.
4.3
CONTRAINDICATIONS
Do not use in dogs less than 12 months of age and/or less than 5 kg
body weight
Do not use in dogs suffering from gastro-intestinal disorders
including ulceration and bleeding.
Do not use where there is evidence of a haemorrhagic disorder.
Do not use in cases of impaired renal or hepatic function
Do not use in cases of cardiac insufficiency
Do not use in pregnant, breeding or lactating dogs.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients
Do not use in case of known hypersensitivity to sulphonamides.
Do not use concomitantly with glucocorticoids or other Non-Steroidal
Anti-Inflammatory Drugs
(NSAIDs), see section 4.8.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a potential risk of increased
renal toxicity.
3
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not administer other NSAIDs or glucocorticoids concurrently or
within 1 month of the last
administration of Trocoxil.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Mavacoxib exhibits an ex
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 06-11-2018
Caracteristicilor produsului Caracteristicilor produsului bulgară 06-11-2018
Raport public de evaluare Raport public de evaluare bulgară 21-07-2013
Prospect Prospect spaniolă 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului spaniolă 05-05-2020
Raport public de evaluare Raport public de evaluare spaniolă 21-07-2013
Prospect Prospect cehă 06-11-2018
Caracteristicilor produsului Caracteristicilor produsului cehă 06-11-2018
Raport public de evaluare Raport public de evaluare cehă 21-07-2013
Prospect Prospect daneză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului daneză 05-05-2020
Raport public de evaluare Raport public de evaluare daneză 21-07-2013
Prospect Prospect germană 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului germană 05-05-2020
Raport public de evaluare Raport public de evaluare germană 21-07-2013
Prospect Prospect estoniană 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului estoniană 05-05-2020
Raport public de evaluare Raport public de evaluare estoniană 21-07-2013
Prospect Prospect greacă 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului greacă 05-05-2020
Raport public de evaluare Raport public de evaluare greacă 21-07-2013
Prospect Prospect franceză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului franceză 05-05-2020
Raport public de evaluare Raport public de evaluare franceză 21-07-2013
Prospect Prospect italiană 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului italiană 05-05-2020
Raport public de evaluare Raport public de evaluare italiană 21-07-2013
Prospect Prospect letonă 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului letonă 05-05-2020
Raport public de evaluare Raport public de evaluare letonă 21-07-2013
Prospect Prospect lituaniană 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului lituaniană 05-05-2020
Raport public de evaluare Raport public de evaluare lituaniană 21-07-2013
Prospect Prospect maghiară 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului maghiară 05-05-2020
Raport public de evaluare Raport public de evaluare maghiară 21-07-2013
Prospect Prospect malteză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului malteză 05-05-2020
Raport public de evaluare Raport public de evaluare malteză 21-07-2013
Prospect Prospect olandeză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului olandeză 05-05-2020
Raport public de evaluare Raport public de evaluare olandeză 21-07-2013
Prospect Prospect poloneză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului poloneză 05-05-2020
Raport public de evaluare Raport public de evaluare poloneză 21-07-2013
Prospect Prospect portugheză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului portugheză 05-05-2020
Raport public de evaluare Raport public de evaluare portugheză 21-07-2013
Prospect Prospect română 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului română 05-05-2020
Raport public de evaluare Raport public de evaluare română 21-07-2013
Prospect Prospect slovacă 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului slovacă 05-05-2020
Raport public de evaluare Raport public de evaluare slovacă 21-07-2013
Prospect Prospect slovenă 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului slovenă 05-05-2020
Raport public de evaluare Raport public de evaluare slovenă 21-07-2013
Prospect Prospect finlandeză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului finlandeză 05-05-2020
Raport public de evaluare Raport public de evaluare finlandeză 21-07-2013
Prospect Prospect suedeză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului suedeză 05-05-2020
Raport public de evaluare Raport public de evaluare suedeză 21-07-2013
Prospect Prospect norvegiană 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului norvegiană 05-05-2020
Prospect Prospect islandeză 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului islandeză 05-05-2020
Prospect Prospect croată 05-05-2020
Caracteristicilor produsului Caracteristicilor produsului croată 05-05-2020

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor